Clinical trial NCT06542497: Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Official title: Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Presbyopia
Lead sponsor: Ocuphire Pharma, Inc.
Sponsor class: INDUSTRY
First posted: 2024-08-07
Enrollment: 545
Sex: ALL
Minimum age (years): 45
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel assignment
Primary purpose: TREATMENT

Brief summary: Safety and efficacy of POS in participants with presbyopia

Detailed description: Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants with Presbyopia

Eligibility criteria: Inclusion Criteria:

Participants must meet all of the following criteria:

1. Males or females ≥ 45 and ≤ 64 years of age
2. Able to comply with all protocol-mandated procedures independently and to attend all scheduled office visits
3. Able and willing to give signed informed consent
4. Able to self-administer study medication throughout the study period

   Inclusion criteria #5, #6, and #7 must all be met at both Screening and Baseline Visits:
5. BCDVA of 55 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/20 Snellen equivalent) or better in photopic conditions in each eye
6. DCNVA of 50 ETDRS letters (20/50 Snellen equivalent) or worse but not \<35 ETDRS letters (20/100 Snellen equivalent) in photopic conditions in each eye and binocularly
7. For participants who depend on reading glasses or bifocals, binocular best-corrected near VA of 65 ETDRS letters (20/25 Snellen equivalent) or better
8. Photopic PD of ≥ 4 mm in the study eye at Screening

Exclusion Criteria:

Excluded from the study will be individuals with any of the following characteristics:

Ophthalmic (in either eye):

1. Use of any topical prescription (including Vuity® or Qlosi™) or over-the-counter (OTC) ophthalmic medications of any kind within 7 days of Screening until study completion, with the exception of lid scrubs with OTC products (eg, OCuSOFT® lid scrub, SteriLid®, baby shampoo, etc.) and artificial tears as specified in Exclusion Criterion #2 below
2. Use of any OTC artificial tears (preserved or unpreserved) during visit days or 15 min before or after instillation of study medication
3. Use of Ryzumvi™ (POS) within 7 days prior to Screening
4. Use of any dry eye product, such as topical ophthalmic therapy for dry eye (eg, generic cyclosporine, Restasis®, Xiidra®, Cequa®, Eysuvis®, and Meibo®) or intranasal dry eye product (eg, Tyrvaya®) or other devices within 12 months prior to Screening
5. Tear break-up time of \< 5 seconds or corneal fluorescein staining (CFS) Grade ≥ 2 in the inferior zone or Grade ≥ 1 in the central zone using the National Eye Institute scale
6. Clinically significant ocular disease (eg, cataract, glaucoma, corneal edema, uveitis, retinal degeneration, loss of visual field, or any macular pathology) that, in the judgment of the Investigator, might interfere with study procedures
7. Recent or current evidence of ocular infection or inflammation in either eye (such as current evidence of clinically significant blepharitis, conjunctivitis, keratitis, etc.). Participants must be symptom free for at least 7 days prior to Screening
8. Any history of herpes simplex or herpes zoster keratitis
9. Known allergy, hypersensitivity, or contraindication to any component of the phentolamine or vehicle formulations
10. Prior participation in a study involving the use of POS for the treatment of presbyopia or night vision disturbance
11. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal
12. Ocular trauma within 6 months prior to Screening
13. Ocular surgery or any ocular laser treatment within 6 months prior to Screening. Any history of radial keratotomy is prohibited
14. Participants with surgical monovision, multifocal, or extended depth-of-focus intraocular lenses (IOLs). Monofocal IOLs are acceptable if in place \> 6 months prior to Screening
15. Monofocal IOL in place \> 6 months prior to Screening with any posterior capsule opacification
16. History of any traumatic (surgical or nonsurgical) or nontraumatic condition affecting the pupil or iris (eg, irregularly shaped pupil, neurogenic pupil disorder, iris atrophy, iridotomy, iridectomy, iritis, etc.)
17. Unwilling or unable to discontinue use of contact lenses at least 1 hour prior to Screening for soft contact lenses or at least 8 hours prior to Screening for hard gas permeable contact lenses, and at least 8 hours (for both types of lenses) prior to all other office visits

    Systemic:
18. Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor antagonists (eg, chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure (BP) or heart rate (HR); second- or third-degree heart blockage or congestive heart failure)
19. Known hypersensitivity or contraindication to any systemic cholinergic parasympathomimetic agent
20. Clinically significant systemic disease (eg, uncontrolled diabetes, myasthenia gravis, cancer, hepatic, renal, endocrine, or cardiovascular disorders) that might interfere with the study as deemed by the judgment of the Investigator
21. Initiation of treatment with, or any changes to, the current dosage, drug, or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to Screening or during the study; however, Flomax® (tamsulosin) is specifically excluded
22. Participation in any investigational study within 30 days prior to Screening
23. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. Acceptable methods include the use of at least one of the following: intrauterine device, hormonal contraception (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence. A female is considered to be of childbearing potential unless she is 1 year postmenopausal or 3 months post-surgical sterilization. All females of childbearing potential, including those with post-tubal ligation, must have a negative urine pregnancy test result at Visit 1 (Screening)
24. Resting HR outside the range of 50 to 110 beats per min (bpm) following at least a 5 min rest period in the sitting position at Visit 1 (Screening). HR may be repeated only once if outside the specified range, following another 5 min rest period in the sitting position
25. Hypertension with resting diastolic BP \> 105 mmHg or systolic BP \> 160 mmHg following at least a 5-min rest period in the sitting position at Visit 1 (Screening). BP may be repeated only once if outside the specified range, following another 5-min rest period in the sitting position

Primary outcomes:
measure: Primary efficacy endpoint
timeFrame: Day 8
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: United States
state: Arizona
city: Scottsdale
country: United States
facility: United States
state: Arizona
city: Glendale
country: United States
facility: United States
state: California
city: Newport Beach
country: United States
facility: United States
state: California
city: Delray Beach
country: United States
facility: United States
state: Florida
city: Longwood
country: United States
facility: United States
state: Florida
city: Rochester
country: United States
facility: United States
state: New York
city: Garner
country: United States
facility: United States
state: North Carolina
city: Athens
country: United States
facility: United States
state: Ohio
city: Warwick
country: United States
facility: United States
state: Rhode Island
city: Goodlettsville
country: United States
facility: United States
state: Tennessee
city: Memphis
country: United States
facility: United States
state: Tennessee
city: San Antonio
country: United States
facility: United States
state: Texas
Study officials:
affiliation: Ocuphire Pharma
name: Jay V Pepose, MD
role: STUDY_CHAIR
References: